Literature DB >> 29866888

Present results and future perspectives in optimizing chronic myeloid leukemia therapy.

Angelo M Carella1, Giuseppe Saglio2, Xavier F Mahon3, Michael J Mauro4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29866888      PMCID： PMC6058801          DOI： 10.3324/haematol.2017.182022

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  22 in total

1.  Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.

Authors:  Jun Imagawa; Hideo Tanaka; Masaya Okada; Hirohisa Nakamae; Masayuki Hino; Kazunori Murai; Yoji Ishida; Takashi Kumagai; Seiichi Sato; Kazuteru Ohashi; Hisashi Sakamaki; Hisashi Wakita; Nobuhiko Uoshima; Yasunori Nakagawa; Yosuke Minami; Masahiro Ogasawara; Tomoharu Takeoka; Hiroshi Akasaka; Takahiko Utsumi; Naokuni Uike; Tsutomu Sato; Sachiko Ando; Kensuke Usuki; Satoshi Morita; Junichi Sakamoto; Shinya Kimura
Journal:  Lancet Haematol       Date:  2015-11-10       Impact factor: 18.959

2.  Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Authors:  Johan Richter; Stina Söderlund; Anna Lübking; Arta Dreimane; Kourosh Lotfi; Berit Markevärn; Anders Själander; Susanne Saussele; Ulla Olsson-Strömberg; Leif Stenke
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

3.  Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Authors:  Gabriel Etienne; Joëlle Guilhot; Delphine Rea; Françoise Rigal-Huguet; Franck Nicolini; Aude Charbonnier; Agnès Guerci-Bresler; Laurence Legros; Bruno Varet; Martine Gardembas; Viviane Dubruille; Michel Tulliez; Marie-Pierre Noel; Jean-Christophe Ianotto; Bruno Villemagne; Martin Carré; François Guilhot; Philippe Rousselot; François-Xavier Mahon
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

4.  Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Authors:  Andreas Hochhaus; Richard A Larson; François Guilhot; Jerald P Radich; Susan Branford; Timothy P Hughes; Michele Baccarani; Michael W Deininger; Francisco Cervantes; Satoko Fujihara; Christine-Elke Ortmann; Hans D Menssen; Hagop Kantarjian; Stephen G O'Brien; Brian J Druker
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

5.  Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

Authors:  D M Ross; S Branford; J F Seymour; A P Schwarer; C Arthur; P A Bartley; C Slader; C Field; P Dang; R J Filshie; A K Mills; A P Grigg; J V Melo; T P Hughes
Journal:  Leukemia       Date:  2010-09-02       Impact factor: 11.528

6.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

7.  Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Authors:  Jorge E Cortes; Dong-Wook Kim; Hagop M Kantarjian; Tim H Brümmendorf; Irina Dyagil; Laimonas Griskevicius; Hemant Malhotra; Christine Powell; Karïn Gogat; Athena M Countouriotis; Carlo Gambacorti-Passerini
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

8.  Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.

Authors:  Ahmad Alhuraiji; Hagop Kantarjian; Prajwal Boddu; Farhad Ravandi; Gautam Borthakur; Courtney DiNardo; Naval Daver; Tapan Kadia; Naveen Pemmaraju; Sherry Pierce; Guillermo Garcia-Manero; William Wierda; Srdan Verstovsek; Elias Jabbour; Jorge Cortes
Journal:  Am J Hematol       Date:  2017-11-09       Impact factor: 10.047

9.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 10.  The concept of treatment-free remission in chronic myeloid leukemia.

Authors:  S Saußele; J Richter; A Hochhaus; F-X Mahon
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528
View more
  3 in total

1.  Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival.

Authors:  Brett M Noel; Steven B Ouellette; Laura Marholz; Deborah Dickey; Connor Navis; Tzu-Yi Yang; Vinh Nguyen; Sarah J Parker; David Bernlohr; Zohar Sachs; Laurie L Parker
Journal:  J Proteome Res       Date:  2019-02-21       Impact factor: 4.466

2.  BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia.

Authors:  Orlando Antelope; Nadeem A Vellore; Anthony D Pomicter; Ami B Patel; Alexandria Van Scoyk; Phillip M Clair; Michael W Deininger; Thomas O'Hare
Journal:  Exp Hematol       Date:  2019-09-04       Impact factor: 3.084

Review 3.  Circular RNA-regulated autophagy is involved in cancer progression.

Authors:  Xuejian Zhou; Juntao Lin; Feifan Wang; Xianwu Chen; Yan Zhang; Zhenghui Hu; Xiaodong Jin
Journal:  Front Cell Dev Biol       Date:  2022-09-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.